Physician

Nephrology

Dr. K Venkat practices Nephrology. He went to Stanley Medical College SMC. He received 1 awards: "CMS Meaningful Use Stage 1 Certification". K Venkat is a published doctor and has 44 publications published. The lastest was: 'Prognostic factors and early resumption of cyclosporin A in renal allograft recipients with thrombotic microangiopathy and hemolytic uremic syndrome.' Venkat accepts all Medicare patients.

Publications

---

• Incidence of Contrast-induced Nephropathy in Kidney Transplant Recipients.
• The evolving approach to ethical issues in living donor kidney transplantation: A review based on illustrative case vignettes.
• Renal allograft outcome in recipients of positive-crossmatch combined liver-kidney transplantation.
• Increasing trend in infection-related death-censored graft failure in renal transplantation.
• Updated principles and clinical caveats in the management of infection in renal transplant recipients.
• Crystal-induced kidney disease in 2 kidney transplant recipients.
• Utility of estimated glomerular filtration rate in live kidney donation.
• Quality of life and psychosocial factors in renal transplant recipients.
• Comparison of long-term actual renal allograft survival in mycophenolate mofetil and azathioprine-based triple drug immunosuppression protocols.
• Outcome of low-dose ganciclovir for cytomegalovirus disease prophylaxis in renal-transplant recipients.
• Care of the renal transplant recipient in the emergency department.
• Proteinuria and microalbuminuria in adults: significance, evaluation, and treatment.
• Transplantation without maintenance corticosteroids in 1-haplotype and 2-haplotype HLA matched living-related renal transplant recipients treated with mycophenolate mo...
• Improved outcome of steroid withdrawal in mycophenolate mofetil-treated primary cadaveric renal transplant recipients.
• Separate risk factors for the development of transplant glomerulopathy vs chronic tubulointerstitial rejection.
• Benefit of angiotensin II receptor blockade in the treatment of posttransplant polycythemia in renal transplant recipients.
• Clinical and renal histologic predictors of long-term outcome after OKT3 therapy for steroid-resistant rejection.
• The Utility of Serial Allograft Biopsies during Delayed Graft Function in Renal Transplantation under Current Immunosuppressive Regimens.
• Allogeneic whole pancreas transplantation in insulin-dependent diabetes mellitus.
• Cyclosporine-induced renal macroangiopathy.
• Recurrence of Scedosporium apiospermum infection following renal re-transplantation.
• Prognostic factors and early resumption of cyclosporin A in renal allograft recipients with thrombotic microangiopathy and hemolytic uremic syndrome.
• Sequestration of active Cryptococcus neoformans infection in the parathyroid gland despite prolonged therapy in a renal transplant recipient.
• An overview of renal transplantation at Henry Ford Hospital.
• Use of cyclosporine and Minnesota antilymphoblast globulin in the early postoperative treatment of primary cadaveric renal transplant recipients.
• Effective long-term immunosuppression maintained by low cyclosporine levels in primary cadaveric renal transplant recipients.
• Hemolytic-uremic syndrome in a renal transplant recipient on FK 506 immunosuppression.
• Cost-utility analysis of living-donor kidney transplantation followed by pancreas transplantation versus simultaneous pancreas-kidney transplantation.
• Rapid progression of native renal artery fibromuscular dysplasia following kidney donation.
• Rapid resolution of proteinuria of native kidney origin following live donor renal transplantation.
• Reversal of cyclosporine-associated hemolytic-uremic syndrome by plasma exchange with fresh-frozen plasma replacement in renal transplant recipients.
• Outcome of plasma exchange therapy in thrombotic microangiopathy after renal transplantation.
• Evaluation of the renal allograft by quantitative duplex sonography and radioisotope renogram.
• Histologic and immunophenotypic evaluation of pretreatment renal biopsies in OKT3-treated allograft rejections.
• Removal of lymphocytotoxic antibodies by pretransplant immunoadsorption therapy in highly sensitized renal transplant recipients.
• Steroid withdrawal in cyclosporine-treated living related donor renal transplant recipients.
• Effect of sequential Minnesota-antilymphocyte globulin and cyclosporine therapy in primary cadaveric renal transplant recipients with delayed graft function.
• Complete replacement of methylprednisolone by azathioprine in cyclosporine-treated primary cadaveric renal transplant recipients.
• Corticosteroid withdrawal with substitution of azathioprine in cyclosporine-treated primary cadaveric renal transplant recipients.
• Influence of the pretransplant hematocrit level on early graft function in primary cadaveric renal transplantation.
• Rapidly rising pretransplant hematocrit and hematocrit > or = 30% signal independent risks for delayed function and primary nonfunction in primary cadaveric renal tran...
• Is the routine use of induction immunosuppression with ALG or OKT3 justified in cadaveric renal transplantation?
• Morbidity of intraoperative OKT3 administration in primary cadaveric renal transplant recipients.

Schools

---

• Madras Medical College Tamil Nadu Dr Mgr Medical University

• Henry Ford Hospital

Procedures Preformed

---

• Kidney Transplant
• Pancreas Transplant

Doctors Specialties

---

• Transplant Surgery
• Nephrology

Accepted Insurances

---

• Aetna
• Blue Card PPO
• Blue Cross Blue Shield of Illinois PPO
• Group Employees PPO
• Cigna HMO
• Cigna PPO
• Great West Healthcare-Cigna PPO
• Open Access Plus
• Cofinity PPO
• Commercial Insurance Company
• First Health (Coventry Health Care) PPO
• Health Alliance
• Preferred PPO
• Choice Care PPO
• Medicare MCR
• Molina
• MultiPlan PPO
• PHCS Network PPO
• Choice Plus POS
• Navigate HMO
• Navigate POS
• Options PPO

Awards

---

• CMS Meaningful Use Stage 1 Certification

Education

---

• Henry Ford Hospital - Wayne State University
• Stanley Medical College SMC

Hospital

---

• Henry Ford Hospital

Drug Facts

---

NPI NUMBER		1336217876
NPPES Provider LastName		VENKAT
NPPES Provider FirstName		K
NPPES Provider ZIPCode		482022608
NPPES Provider State		MI
Specialty Description		Nephrology
Total Claim Count		216.0
Distinct Opioid Count		0.0
Opioid Claim Count		0.0
Percent Opioid Claims		0.0

Helpful Reviews

---

Give Anonymous Review

Medicare Facts

---

National Provider Identifier [NPI]	1336217876
Last Name Of The Provider	VENKAT
First Name Of The Provider	K
View All

Similar Doctors

---

	Dr. Mili J. Shah, MD
	Dr. Joel M. Topf, MD This Doctor is OpenDoctor Recommended.
	Dr. Jukaku Tayeb, MD This Doctor is OpenDoctor Recommended.
	Dr. Mohannad A. Alool, MD This Doctor is OpenDoctor Recommended.
	Dr. Naveed U. Haq, MD This Doctor is OpenDoctor Recommended.
	Dr. Farrukh Koraishy, MD This Doctor is OpenDoctor Recommended.
	Dr. Anita K. Patel, MD This Doctor is OpenDoctor Recommended.
	Dr. Stephen D. Migdal, MD This Doctor is OpenDoctor Recommended.
	Dr. James E. Novak, MD This Doctor is OpenDoctor Recommended.
	Dr. Vivek Soi, MD This Doctor is OpenDoctor Recommended.
	Dr. Carlo G. Castillo, DO
	Dr. Robert L. Cosby, MD
	Dr. Joseph M. Beals, MD This Doctor is OpenDoctor Recommended.
	Dr. Nashat B. Imran, MD
	Dr. Quresh T. Khairullah, MD This Doctor is OpenDoctor Recommended.
	Dr. Vanji Karthikeyan, MD This Doctor is OpenDoctor Recommended.
	Dr. Syed M. Raza, MD
	Dr. Mahmoud A. Tabbal, MD
	Dr. Wled Wazni, MD

---

Doctor Directory | TOS | twitter | FB | Angel | blog